<DOC>
	<DOCNO>NCT00566657</DOCNO>
	<brief_summary>Primary objective demonstrate superiority riferminogene pecaplasmid ( XRP0038/NV1FGF ) placebo prevention major amputation ankle treat leg death cause , whichever come first , critical limb ischemia ( CLI ) patient skin lesion . Secondary objective evaluate : - The efficacy riferminogene pecaplasmid versus placebo delay time major amputation ; - The efficacy riferminogene pecaplasmid versus placebo delay time death ; - The safety riferminogene pecaplasmid study population .</brief_summary>
	<brief_title>Efficacy Safety XRP0038/NV1FGF Critical Limb Ischemia Patients With Skin Lesions</brief_title>
	<detailed_description>The study consist 6-week treatment follow-up period 12 month . A follow-up contact schedule 6 month later . Per protocol amendment 18-month long-term safety survey add .</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Having peripheral artery disease stage Critical Limb Ischemia ( CLI ) skin lesion ( either ulcer ( ) gangrene ) ; With objective evidence CLI ankle systolic pressure &lt; 70 mmHg and/or toe systolic pressure &lt; 50 mmHg transcutaneous oxygen pressure ( TcPO2 ) &lt; 30 mmHg ; Unsuitable standard revascularization his/her peripheral arterial disease ; Having negative screening cancer . Previous major amputation leg treat planned major amputation within first month follow randomization ; Known Buerger 's disease ; Successful low extremity revascularization procedure within 3 month prior randomization ; Uncontrolled blood pressure define systolic blood pressure ( SBP ) ≥180 mmHg diastolic blood pressure ( DBP ) ≥110 mmHg despite adequate antihypertensive treatment ; Acute cardiovascular event within 3 month prior randomization ; Active proliferative retinopathy severe macular oedema ; Previous current history malignant disease within past 5 year ; Previous treatment systemic angiogenic factor stem cell therapy ; Pregnant breastfeed woman woman childbearing potential protected effective contraceptive method birth control . Man follow effective contraceptive method partner childbearing potential course study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>Plasmid base gene therapy</keyword>
</DOC>